Cellular Biomedicine Group, Inc.
CBMG
CBMG was delisted on the 19th of February, 2021.
20 hedge funds and large institutions have $5.84M invested in Cellular Biomedicine Group, Inc. in 2017 Q3 according to their latest regulatory filings, with 5 funds opening new positions, 1 increasing their positions, 8 reducing their positions, and 9 closing their positions.
17% less funds holding
Funds holding: 24 → 20 (-4)
18% less capital invested
Capital invested by funds: $7.11M → $5.84M (-$1.27M)
44% less first-time investments, than exits
New positions opened: 5 | Existing positions closed: 9
88% less repeat investments, than reductions
Existing positions increased: 1 | Existing positions reduced: 8
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Dimensional Fund Advisors
Austin,
Texas
|
+$154K |
| 2 |
Zurich Cantonal Bank
Zurich,
Switzerland
|
+$95K |
| 3 |
Wells Fargo
San Francisco,
California
|
+$34.2K |
| 4 |
UBS Group
Zurich,
Switzerland
|
+$13K |
| 5 |
Royal Bank of Canada
Toronto,
Ontario, Canada
|
+$28 |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Goldman Sachs
New York
|
-$540K |
| 2 |
PP
Paloma Partners
Greenwich,
Connecticut
|
-$390K |
| 3 |
Susquehanna International Group
Bala Cynwyd,
Pennsylvania
|
-$320K |
| 4 |
Millennium Management
New York
|
-$278K |
| 5 |
ECM
Element Capital Management
New York
|
-$238K |
| Name | Holding | Trade Value |
Shares Change |
Change in Stake |
|
|---|---|---|---|---|---|
26
Bank of America
Charlotte,
North Carolina
| – | -$28K | -3,206 | Closed |
|
27
Creative Planning
Overland Park,
Kansas
| – | -$3K | -300 | Closed |
|
|
28
Royal Bank of Canada
Toronto,
Ontario, Canada
| – | +$28 | +3 | New |
|
CBMG Hedge Fund Activity: Q3 2017 in Review
20 of the 4,011 institutional investors tracked by Wall St. Rank reported a position in Cellular Biomedicine Group, Inc. (CBMG) for Q3 2017, worth a combined $5.84M — down 18% from $7.11M a quarter earlier.
Sellers outnumbered buyers: 9 funds closed out of CBMG and 5 opened new positions — a net loss of 4 holders — while 8 trimmed existing stakes and 1 added.
The largest buyer was Dimensional Fund Advisors, opening a new position worth an estimated $154K. The largest seller was Goldman Sachs, exiting entirely with an estimated $540K sold.
- 20 institutional investors held Cellular Biomedicine Group, Inc. (CBMG) as of Q3 2017, down from 24 in Q2 2017.
- Funds reported $5.84M of Cellular Biomedicine Group, Inc. stock for Q3 2017, down 18% quarter-over-quarter.
- 5 funds opened new Cellular Biomedicine Group, Inc. positions in Q3 2017 and 9 closed out, a net change of -4 holders.
- The largest Cellular Biomedicine Group, Inc. buyer in Q3 2017 was Dimensional Fund Advisors, an estimated $154K added.
- The largest Cellular Biomedicine Group, Inc. seller in Q3 2017 was Goldman Sachs, an estimated $540K sold.
Based on aggregated 13F filings for Q3 2017.